News
Click here for news in Danish.
December 21, 2012 | Company Announcements
Bavarian Nordic Issues Revised Financial Calendar for 2013November 28, 2012 | Company Announcements
Bavarian Nordic Receives Additional Order for IMVAMUNE® Smallpox Vaccines from the Canadian GovernmentNovember 13, 2012 | Company Announcements
Bavarian Nordic – Interim Financial Report for the Period 1 January to 30 September 2012October 01, 2012 | Company Announcements
Bavarian Nordic Reports Preliminary Data from Phase 2 Trial of CV-301 in Metastatic Breast CancerSeptember 17, 2012 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchAugust 31, 2012 | Company Announcements
Bavarian Nordic issues Financial Calendar for 2013August 28, 2012 | Company Announcements
Bavarian Nordic awards warrants to the Board of Directors, management and certain employeesAugust 28, 2012 | Company Announcements
Bavarian Nordic Reports First Half 2012 Financial ResultsJuly 13, 2012 | Company Announcements
Bavarian Nordic Announces New Major Shareholder from the USAJuly 11, 2012 | Company Announcements
U.S. Government Expands Population Eligible to Receive Bavarian Nordic’s Smallpox Vaccine in an EmergencyJune 18, 2012 | Company Announcements
Bavarian Nordic Awarded Contract from the U.S. Government to Advance the Development of new MVA-BN® based vaccinesJune 02, 2012 | Press Releases
Interim Analysis for Bavarian Nordic’s Phase 2 PROSTVAC® Trial Presented at Annual ASCO MeetingMay 22, 2012 | Company Announcements
Bavarian Nordic A/S – Interim Report for the period 1 January to 31 March 2012May 22, 2012 | Press Releases
U.S. Government Supports Phase 3 Study of Bavarian Nordic’s Smallpox VaccineMay 18, 2012 | Press Releases
Bavarian Nordic to Report New PROSTVAC® Clinical Data at the American Society of Clinical Oncology Annual MeetingApril 16, 2012 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held 16 April 2012April 10, 2012 | Company Announcements
Bavarian Nordic Nominates Peter Kürstein for Election to the BoardMarch 21, 2012 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General MeetingMarch 08, 2012 | Company Announcements
Bavarian Nordic Announces 2011 Full Year ResultsMarch 01, 2012 | Company Announcements
Bavarian Nordic Submits a Marketing Application for its Smallpox Vaccine to the European Medicines AgencyFebruary 23, 2012 | Company Announcements
PROSTVAC® and Ipilimumab Phase 1 Study Supports Rationale for Combining Two Immunotherapies for Prostate Cancer